GT Biopharma Inc expected to post a loss of 28 cents a share - Earnings Preview

GT Biopharma

07/08/2021 01:50

* GT Biopharma Inc  GTBP.OQ   GTBP.O  is expected to report
results on August 9.
​* Refinitiv's mean analyst estimate for GT Biopharma Inc is for
a loss of 28 cents per share. 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for GT Biopharma
Inc is $25​, about 55.6% above​ its last closing price
of $11.11. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.25       -0.24      -1.83     Missed  -646.9
 Dec. 31 2020  -0.04       -0.04      -3.39     Missed  -7,433
                                                        .3
                                                        ​
 ​​            ​                                        ​
                                                        ​
 This summary was machine generated August 7 at 00:50 GMT.  All
figures in US dollars unless otherwise stated